The promising potential of such an approach has been demonstrated recently for the bispecific CD30/CD16A innate cell engager acimtamig (AFM13), when combined with cord blood-derived NK cells, resulting in preclinical and clinical efficacy with an overall response rate of 94% and a complete response rate of 71% at the recommended phase 2 dose in heavily pretreated patients with Hodgkin lymphoma and non-Hodgkin lymphoma48,65. The gene discussed is FCGR3A; the disease is Hodgkins lymphoma.